As we venture further into 2023, Glooko CEO Russ Johannesson shares his perspective on the connected care trends in digital therapeutics, remote patient monitoring, precision engagement and decentralized clinical trials expected this year.

Through a new partnership, the Hedia app, which provides bolus insulin dosing recommendations, will integrate with Glooko’s connected care platform, which lets patients share diabetes data with their healthcare providers.

In addition to gathering data from glucose monitors, insulin pumps, fitness trackers and other devices, Glooko’s diabetes management platform will offer guidance for a user’s upcoming bolus doses of insulin, thanks to a partnership with Hedia, a Danish algorithm-based insulin dosing company.

2023 is expected to be a year of advancements in connected care supporting patients with chronic conditions and their care teams. Glooko CEO Russ Johannesson shares his outlook on trends in digital therapeutics, precision engagement, remote patient monitoring and clinical trial management.

Smart insulin pens are a recent advancement making an impact on people living with diabetes. These connected pens can be used by anyone with the chronic condition that injects insulin and can sync with certain digital health apps, like Glooko, that store insulin, blood glucose, fitness and food data in one place.

Sanofi formed a partnership with Glooko to support its vision of insulin-based therapies connected with glucose monitoring devices that simplify blood glucose management for people with diabetes.

Glooko entered into a partnership with Sanofi to integrate a connected cap for smart insulin pens into its digital platform for people with diabetes and their healthcare providers.

A new alliance between Glooko and Sanofi allows for visualization of connected pen data in the Glooko app that patients with diabetes can share with their healthcare team.

Glooko achieving ISO 27001 certification allows the digital health company to assure patients with diabetes and related chronic conditions that their health data remains secure on its data management and remote patient monitoring platforms.

Wearable technologies that were built for fitness have evolved and now have greater diagnostic and medical uses. Glooko Chief Executive Officer Russ Johannesson discusses why these products are at the heart of connected care, the growing areas of digital health, therapeutics and clinical research, and the increasing demand for and adoption of remote patient monitoring.